论文部分内容阅读
目的:探究前列地尔联合缬沙坦应用在早期糖尿病肾病患者治疗中的临床效果。方法:随机选取2013年9月-2016年9月我院收治的82例早期糖尿病肾病患者作为观察对象,全部患者依照治疗方法的不同随机分成观察组与对照组,每组有41例患者。其中,对照组选择前列地尔治疗,观察组选择前列地尔联合缬沙坦治疗。结果:对照组的临床治疗总有效率为75.61%,而观察组的临床治疗总有效率为95.12%,其中观察组患者的临床治疗效果明显的比对照组高(P<0.05)。结论:前列地尔联合缬沙坦应用在早期糖尿病肾病患者治疗中具有着较好的临床效果,可有效改善患者临床症状,减少并发症发生率,提高患者生存质量,在临床中值得广泛推广应用。
Objective: To investigate the clinical effect of alprostadil plus valsartan in the treatment of patients with early diabetic nephropathy. Methods: 82 patients with early diabetic nephropathy admitted in our hospital from September 2013 to September 2016 were selected randomly as observation object. All patients were randomly divided into observation group and control group according to different treatment methods, with 41 patients in each group. Among them, the control group selected alprostadil treatment, the observation group selected alprostadil combined valsartan treatment. Results: The total effective rate of clinical treatment in the control group was 75.61%, while the total effective rate in the observation group was 95.12%. The clinical effect of the observation group was significantly higher than that of the control group (P <0.05). Conclusion: The application of alprostadil combined with valsartan in the treatment of patients with early diabetic nephropathy has a good clinical effect, which can effectively improve the clinical symptoms, reduce the incidence of complications and improve the quality of life of patients, which is worthy of wide application in clinic .